Advertisement
Advertisement
U.S. Markets open in 4 hrs 41 mins
Advertisement
Advertisement
Advertisement
Advertisement

Nabriva Therapeutics plc (NBRV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4899-0.0087 (-1.74%)
At close: 04:00PM EST
0.4840 -0.01 (-1.20%)
After hours: 05:22PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4986
Open0.4987
Bid0.0000 x 1200
Ask0.0000 x 2900
Day's Range0.4700 - 0.4999
52 Week Range0.4110 - 3.4900
Volume282,031
Avg. Volume882,593
Market Cap27.787M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-1.6220
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.67
  • GlobeNewswire

    Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

    — Meeting to Reconvene on March 24, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 18, 2022 to allow the Company to solicit from its shareholders

  • GlobeNewswire

    Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

    — Meeting to Reconvene on January 18, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders (EGM) on January 14, 2022 to allow the Company to solicit from its shareholder

  • GlobeNewswire

    Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021

    -SIVEXTRO® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as of 12/31/21 provides cash runway well into Q422- DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infe

Advertisement
Advertisement